STAT+: Her daughter Mila got a bespoke medicine. Now she’s starting a new biotech to make more

STAT PlusBiotech Her daughter Mila got a bespoke medicine. Now she’s starting a new biotech to make more After a prior effort shuttered, Julia Vitarello is trying again Manage alerts for this article Email this article Share this article By Andrew JosephMay 1, 2026 Europe Correspondent Andrew Joseph[email protected]Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. ROME — Julia Vitarello, whose daughter Mila eight years ago received a bespoke medicine designed for her particular disease-causing mutation, said this week that she is in the process of starting a new company to try to create these individualized therapies at scale. Vitarello’s previous effort, called EveryONE Medicines, recently folded in part because new Food and Drug Administration guidance encouraging the development of customized therapies did not go far enough in creating a pathway to satisfy EveryONE’s investors, Vitarello said. Advertisement Now Vitarello and collaborators are looking for new funders. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, rare disease, STAT+ Submit a correction requestReprints Andrew Joseph Europe Correspondent Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Matt's Take April 30, 2026 Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstood Politics April 30, 2026 STAT Plus: Katherine Szarama named acting director of FDA’s vaccines and biologics center Advertisement The Readout April 30, 2026 STAT Plus: Five-way obesity drug is super effective — in mice Adam's Biotech Scorecard April 30, 2026 STAT Plus: What does Akeso’s primo plenary spot say about its survival data? The Readout April 29, 2026 STAT Plus: A patent win for Pfizer and BridgeBio Subscriber Picks